Overview
Samba BioLogics, Inc. is a preclinical stage biotechnology company based in Vermont. It produces breakthrough agonist biologics that preserve tissue and improve repair after ischemic injury. Our patent portfolio includes “Cell-Kro,” a biologic drug that promotes engraftment of transplanted progenitor cells, and “VasaPlex,” a biologic that rescues jeopardized cardiac tissue after myocardial infarction.